Published in Neurology on June 09, 2009
Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. J Neuroinflammation (2011) 1.11
3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases. Arch Neurol (2010) 1.08
Atorvastatin added to interferon β for relapsing multiple sclerosis: a randomized controlled trial. J Neurol (2012) 0.89
Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study. Neurology (2012) 0.87
Inhibition of interferon-beta responses in multiple sclerosis immune cells associated with high-dose statins. Arch Neurol (2012) 0.85
Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR Trial. PLoS One (2011) 0.84
Chronic mild stress eliminates the neuroprotective effect of Copaxone after CNS injury. Brain Behav Immun (2013) 0.82
Outcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials. Mult Scler Int (2014) 0.81
Interference with RhoA-ROCK signaling mechanism in autoreactive CD4+ T cells enhances the bioavailability of 1,25-dihydroxyvitamin D3 in experimental autoimmune encephalomyelitis. Am J Pathol (2012) 0.81
Atorvastatin added to interferon beta for relapsing multiple sclerosis: 12-month treatment extension of the randomized multicenter SWABIMS trial. PLoS One (2014) 0.80
Combinatorial Effect of Metformin and Lovastatin Impedes T-cell Autoimmunity and Neurodegeneration in Experimental Autoimmune Encephalomyelitis. J Clin Cell Immunol (2013) 0.79
Modulation of dendritic cell immunobiology via inhibition of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase. PLoS One (2014) 0.78
Importance of Apolipoprotein A-I in Multiple Sclerosis. Front Pharmacol (2015) 0.76
Multiple sclerosis: combination therapy in MS--still a valid strategy. Nat Rev Neurol (2011) 0.75
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med (2006) 6.25
The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature (2002) 5.24
Adhesion to the extracellular matrix regulates the coupling of the small GTPase Rac to its effector PAK. EMBO J (2000) 4.39
Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology (2008) 3.38
Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol (2005) 2.67
Characterization of beta-R1, a gene that is selectively induced by interferon beta (IFN-beta) compared with IFN-alpha. J Biol Chem (1996) 1.92
Cell-type and donor-specific transcriptional responses to interferon-alpha. Use of customized gene arrays. J Biol Chem (2002) 1.20
Increased gene expression of novel cytosolic and secretory phospholipase A(2) types in human airway epithelial cells induced by tumor necrosis factor-alpha and IFN-gamma. J Interferon Cytokine Res (2002) 1.10
Requirement of catalytically active Tyk2 and accessory signals for the induction of TRAIL mRNA by IFN-beta. J Interferon Cytokine Res (2007) 0.95
Tackling multiple sclerosis. Nature (2002) 0.84
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36
Axonal transection in the lesions of multiple sclerosis. N Engl J Med (1998) 12.21
Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology (2007) 4.72
Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain (1999) 4.41
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology (2011) 4.25
A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem (2000) 4.21
Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nat Med (1997) 3.65
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology (2005) 3.45
Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28
Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain (1980) 3.27
Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest (1999) 3.21
The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology (2003) 3.21
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology (2005) 2.95
The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol (2011) 2.90
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology (2006) 2.75
Optical coherence tomography and disease subtype in multiple sclerosis. Neurology (2007) 2.56
The King-Devick test as a determinant of head trauma and concussion in boxers and MMA fighters. Neurology (2011) 2.51
Interferon-induced antiviral actions and their regulation. Adv Virus Res (1993) 2.40
Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology (2008) 2.29
MRI findings in Susac's syndrome. Neurology (2003) 2.17
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17
Sensationalism in the media: when scientists and journalists may be complicit collaborators. Eff Clin Pract (2001) 2.14
MRI of the corpus callosum in multiple sclerosis: association with disability. Mult Scler (2010) 2.13
The clinical spectrum of unruptured intracranial aneurysms. Arch Neurol (1993) 2.11
Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology (2009) 2.10
Stat1-independent regulation of gene expression in response to IFN-gamma. Proc Natl Acad Sci U S A (2001) 1.96
Multiple sclerosis: a comparison of the latent periods of different populations. Neuroepidemiology (1993) 1.94
Characterization of beta-R1, a gene that is selectively induced by interferon beta (IFN-beta) compared with IFN-alpha. J Biol Chem (1996) 1.92
Relation of vision to global and regional brain MRI in multiple sclerosis. Neurology (2007) 1.89
Synchronous synthesis of alpha- and beta-chemokines by cells of diverse lineage in the central nervous system of mice with relapses of chronic experimental autoimmune encephalomyelitis. Am J Pathol (1997) 1.88
Chemokine monocyte chemoattractant protein-1 is expressed by astrocytes after mechanical injury to the brain. J Immunol (1996) 1.84
Quality of life in multiple sclerosis in France, Germany, and the United Kingdom. Cost of Multiple Sclerosis Study Group. J Neurol Neurosurg Psychiatry (1998) 1.84
Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. Neurology (2011) 1.83
Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer (2007) 1.81
Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology (2009) 1.78
Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology (2010) 1.75
Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide. Neurology (2007) 1.74
Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology (2003) 1.73
Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol (1997) 1.72
Chemokine regulation of experimental autoimmune encephalomyelitis: temporal and spatial expression patterns govern disease pathogenesis. J Immunol (1998) 1.72
Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler (2009) 1.65
Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol (1996) 1.64
Quantitative characterization of the corticospinal tract at 3T. AJNR Am J Neuroradiol (2006) 1.62
Chemokines and chemokine receptors in inflammation of the nervous system: manifold roles and exquisite regulation. Immunol Rev (2000) 1.61
New low-contrast vision charts: reliability and test characteristics in patients with multiple sclerosis. Mult Scler (2000) 1.60
Trapeziectomy for trapeziometacarpal joint osteoarthritis: is ligament reconstruction and temporary stabilisation of the pseudarthrosis with a Kirschner wire important? J Hand Surg Eur Vol (2009) 1.60
The central visual field in homonymous hemianopia. Evidence for unilateral foveal representation. Arch Neurol (1997) 1.59
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol (2012) 1.57
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology (2007) 1.56
Saccade preparation inhibits reorienting to recently attended locations. J Exp Psychol Hum Percept Perform (1989) 1.55
Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis. J Am Acad Dermatol (1996) 1.55
Antibodies to GM1 and GD1b in patients with motor neuron disease without plasma cell dyscrasia. Ann Neurol (1989) 1.55
A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis. Neurology (1997) 1.54
Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology (2008) 1.53
Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators. Neurology (2000) 1.52
The Prevention of Post-Partum Relapses with Progestin and Estradiol in Multiple Sclerosis (POPART'MUS) trial: rationale, objectives and state of advancement. J Neurol Sci (2009) 1.52
The prevalence of patients with rheumatoid arthritis in the West Midlands fulfilling the BSR criteria for anti-tumour necrosis factor therapy: an out-patient study. Rheumatology (Oxford) (2003) 1.51
Ibuprofen-induced meningitis: detection of intrathecal IgG synthesis and immune complexes. Neurology (1989) 1.51
Neuromyelitis optica and pregnancy. Neurology (2012) 1.49
Associations between retinal nerve fiber layer abnormalities and optic nerve examination. Neurology (2010) 1.49
Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol (2000) 1.49
p48/STAT-1alpha-containing complexes play a predominant role in induction of IFN-gamma-inducible protein, 10 kDa (IP-10) by IFN-gamma alone or in synergy with TNF-alpha. J Immunol (1998) 1.48
Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite. Neurology (2003) 1.46
Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis. Ann Neurol (1998) 1.45
Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology (2007) 1.45
Isolated trochlear nerve palsy in patients with multiple sclerosis. Neurology (1999) 1.45
Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients. Neurology (2006) 1.45
Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry (1997) 1.44
Visual impairment associated with mutism after posterior fossa surgery in children. Neurosurgery (1998) 1.44
Sixth nerve palsy as a presenting sign of intracranial plasmacytoma and multiple myeloma. J Neuroophthalmol (2000) 1.43
Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients. J Neurol Neurosurg Psychiatry (2013) 1.42
Defining the natural history of MS: the need for complete data and rigorous definitions. Mult Scler (2008) 1.41
Relationship of urinary myelin basic protein-like material with cranial magnetic resonance imaging in advanced multiple sclerosis. Arch Neurol (2001) 1.40
Mice overexpressing chemokine ligand 2 (CCL2) in astrocytes display enhanced nociceptive responses. Neuroscience (2007) 1.40
[Familial epilepsy seizure disclosing long QT syndrome]. Rev Neurol (Paris) (1996) 1.39
Clinicopathologic study of paraneoplastic brainstem encephalitis and ophthalmoparesis. J Neuroophthalmol (1996) 1.39
P2X7-like receptor activation in astrocytes increases chemokine monocyte chemoattractant protein-1 expression via mitogen-activated protein kinase. J Neurosci (2001) 1.38
Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas: relation to tumor location by magnetic resonance imaging. Am J Ophthalmol (2001) 1.31
Ross syndrome plus: beyond horner, Holmes-Adie, and harlequin. Neurology (2000) 1.29
Idiopathic intracranial hypertension: relation of age and obesity in children. Neurology (1999) 1.29
CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am J Pathol (2001) 1.28
TGF-beta suppresses IFN-gamma induction of class II MHC gene expression by inhibiting class II transactivator messenger RNA expression. J Immunol (1997) 1.27
Longitudinal changes in diffusion tensor-based quantitative MRI in multiple sclerosis. Neurology (2011) 1.27
Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. Neurology (1994) 1.27
Central nervous system chemokine mRNA accumulation follows initial leukocyte entry at the onset of acute murine experimental autoimmune encephalomyelitis. Brain Behav Immun (1995) 1.26